secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2026-08-28T13:21:49+00:00
Accession:  0001193125-26-372456
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics' aficamten meets both primary endpoints in Phase 3 ACACIA-HCM nHCM trial
--------------------------------------------------------------------------------

- ACACIA-HCM met both dual primary endpoints: KCCQ-CSS LSM diff 3.0 (p=0.021) and pVO2 diff 0.67 ml/kg/min (p=0.003) at Week 36.
- First Phase 3 trial to show statistically significant improvements in non-obstructive HCM; results published in NEJM and presented at ESC 2026.
- sNDA for aficamten in symptomatic nHCM to be submitted to FDA in Q4 2026.
- Safety: LVEF <50% in 10.5% of aficamten patients vs 0.8% placebo; SAEs 20.2% vs 14.7%.
- Global efficacy: 53% of aficamten patients responded in 3+ outcome measures vs 13% placebo (p<0.001).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000119312526372456/0001193125-26-372456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000119312526372456/cytk-20260828.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-372456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer